Stock TSVT 2SEVENTY BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News 2seventy bio, Inc.

Equities

TSVT

US9013841070

Real-time Estimate Cboe BZX
Other stock markets
 10:22:23 2024-05-20 am EDT 		5-day change 1st Jan Change
4.695 USD -2.19% Intraday chart for 2seventy bio, Inc. +5.12% +10.54%
May. 08 Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, vs. Street Est of $14.1M MT
May. 08 Transcript : 2seventy bio, Inc., Q1 2024 Earnings Call, May 08, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, vs. Street Est of $14.1M
MT
Transcript : 2seventy bio, Inc., Q1 2024 Earnings Call, May 08, 2024
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
BU
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
AQ
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
BU
US FDA mandates label updates on CAR-T cancer therapies
RE
FDA Approves BMS And J&J CAR-T Cell Therapies For The Earlier Treatment Of Multiple Myeloma
AQ
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma after Two Prior Lines of Therapy
AQ
Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication
MT
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma
DJ
Bristol Myers: FDA approves Abecma in multiple myeloma
CF
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer
RE
U.S. FDA allows expanded use of Bristol Myers' cell therapy
RE
U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio?S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
CI
2seventy bio : Corporate Presentation April 2024
PU
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
BU
Regeneron Pharmaceuticals, Inc. completed the acquiistion of R&D pipeline from 2seventy bio, Inc..
CI
Regeneron Pharmaceuticals, Inc. completed the acquiistion of R&D pipeline from 2seventy bio, Inc. for $15 million.
CI
Bristol Myers Squibb Gets EU OK for Cancer Treatment
DJ
Engine Capital Nominates Candidates to the Board of 2seventy bio
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TSVT Stock
  4. News 2seventy bio, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW